ArticleFrontiers in oncology2025
Analysis of treatment options and survival outcomes for patients with localized prostate cancer: a focus on androgen deprivation therapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Management of localized prostate cancer (PCa) remains challenging in resource-limited settings where access to surgery and radiotherapy is restricted. This study assessed the survival outcomes of patients receiving androgen deprivation therapy (ADT) alone compared with other modalities. Methods: We retrospectively analyzed patients with localized PCa treated with ADT at Taiyuan Central Hospital of Shanxi Medical University from 2002 to 2023. Cox regression identified prognostic factors for overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS). Outcomes were compared with SEER database cohorts receiving radical prostatectomy (RP), radiotherapy (RT), or no treatment. Propensity score matching (PSM) was used to balance baseline characteristics. Results: Among 86 patients in the ADT cohort, the median follow-up was 2,152.5 days. Median OS was 2,378 days, with 5-year OS, DSS, and PFS rates of 58.4%, 85.2%, and 72.5%, respectively. Cox analysis identified prostate-specific antigen, ISUP grade, and body mass index as independent predictors of PFS. After PSM for age and ISUP grade, the ADT group showed significantly better OS and DSS than RP, RT, or no treatment cohorts in the SEER database. Conclusions: ADT demonstrated favorable survival outcomes compared with RP and RT in elderly patients with high-grade localized PCa. These results highlight ADT as a potential alternative where invasive options are less feasible, providing insights into optimizing treatment strategies for resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.